// App-Quantinova.ai

307 : Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).

Researchers

Presenter

  • Sumanta K. Pal

Principal Investigators

  • Javier Puente

  • Daniel Yick Chin Heng

  • Hilary Glen

  • Piotr Koralewski

  • Daniil Stroyakovskiy

  • Boris Alekseev

  • Francis Parnis

  • Daniel Castellano

  • Tudor Ciuleanu

  • Jae-Lyun Lee

  • Kaisa Sunela

  • Karen O'Hara

  • Terri A. Binder

  • Lixian Peng

  • Alan D. Smith

  • Sun Young Rha

Medical Centers

  • Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain

  • Department of Radiation Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

  • Medical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Department of Chemotherapy, Rydygiera Hospital, Krakow, Poland

  • Chemotherapeutic Department, Moscow City Oncology Hospital, Moscow, Russian Federation

  • Moscow Hertzen Oncology Institute, Moscow, Russian Federation

  • Haematology -oncology, Adelaide Cancer Centre, Adelaide, Australia

  • Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain

  • Medical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania

  • Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea

  • Department of Oncology, Tampere University Hospital, Tampere, Finland

  • Eisai Ltd., Hatfield, United Kingdom

  • Eisai Inc, Woodcliff Lake, NJ

  • Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea

Locations

  • United States

  • Spain

  • Canada

  • United Kingdom

  • Poland

  • Russia

  • Australia

  • Romania

  • Republic of South Korea

  • Finland

Companies

  • Eisai Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Clear cell renal carcinoma

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Everolimus

  • Lenvatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03173560

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved